Back HCV Treatment

Technivie Regimen Shows Good Response Rate for People with HCV Genotype 4

An interferon-free combination of paritaprevir, ritonavir, and ombitasvir -- the drugs in AbbVie's recently approved Technivie coformulation -- taken for 12 weeks cured more than 90% of patients with hepatitis C virus (HCV) genotype 4 in the PEARL-I trial, according to a study report in the June 20 edition of The Lancet.

alt

Read more: